Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

Renaissance will optimize the formulation of intranasal Foralumab and assist with scaling up production for clinical trials.

AIM ImmunoTech (AIM) announced that Paul Goepfert, MD, of the University of Alabama-Birmingham, has agreed to act as the Principal Investigator ...

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Paul Goepfert, MD, ...

NeOnc claims that its novel intranasal delivery platform will be able to bypass the blood-brain barrier and better target ...

Silo Pharma (NASDAQ: SILO) , a biopharmaceutical company developing novel therapeutics and drug delivery systems, announced that the U.S. Patent and ...

Shares of Tiziana Life Sciences (NASDAQ:TLSA) jumped 12% Thursday after the company said that a study of its drug candidate ...

Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery ...

Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing ...

The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent ...

Albert Valiakhmetov's analysis reveals that social media platforms are no longer just communication tools. They are ...

Researchers at the Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of ...